Evaluation of Clinical Outcomes of Pulse Widths in Spinal Cord Stimulation

The proposed study is a prospective, multi-center, two-arm, randomized, crossover design to
be conducted at up to 10 sites. The study will enroll up to 100 subjects in order to include
up to 10 subjects in the study per site. Subjects selected to participate in the trial have
back and/or leg pain, have been evaluated as a candidate for SCS and have agreed to undergo a
temporary SCS trial using the Algovita® system with percutaneous leads. Each subject will be
followed during the trial period of approximately 7+/-2 days. The study will end when the
last subject has completed the trial period and exited. The expected enrollment period for
this study is approximately six months. After exit from the clinical study, subjects will
continue to be followed by their physician per usual care. All device and procedure-related
AEs will be collected and reported per the study protocol.

Inclusion Criteria:

- be eligible for SCS therapy according to the Algovita® SCS system Indications for Use
statement

- be undergoing a SCS trial using Algovita® SCS system

- sign a valid, Institutional Review Board (IRB)-approved informed consent form.

- be 18 years of age or older when written informed consent is obtained

Exclusion Criteria:

- be contraindicated for an Algovita® SCS system

- have a cognitive impairment or exhibits any characteristic, that would limit the study
candidate's ability to assess pain relief or complete study assessments

- have a life expectancy of less than 2 years

- be participating in another clinical study that would confound data analysis

- have a coexisting pain condition that might confound pain ratings

- have a significant psychiatric disorder